Sector: Specialty Chemicals / Pharma Intermediates

Divi’s Laboratories Latest:

reported strong Q2 FY26 results (profit up ~35% YoY) and remains a broker favorite for margins/exports. Why it matters: Export-oriented pharmaceutical intermediates benefit from global demand and contract wins. Risk: Customer concentration and raw material/FX risks. Actionable takeaway: For beginners interested in pharma upstream exposure, Divi’s shows quality margins — consider as a specialized core holding.